Who we are
“At Janssen, helping patients overcome the challenges they face is our mission and privilege. We focus our efforts on discovering first of a kind medicines for cancers where there are limited treatment options and strive to make cancer a manageable, even curable condition.
COMPANY GROUP CHAIRMAN, EMEA
Janssen is working to change expectations of what a cancer diagnosis means. Building on the tremendous advances being made by the oncology community and looking toward the day when patients and physicians no longer experience terror and distress at hearing the words “you have cancer”.
We focus our efforts on discovering first of a kind medicines for cancers where there are limited treatment options. We pursue the cancer types and sub-types which we know best and where we can achieve the highest impact towards a cure: haematological malignancies, prostate cancer, bladder cancer and lung cancer. We are also trying to go one step further, stopping cancer before it can get a hold (a process known as cancer interception).
With the help of some wonderful partners and ground-breaking collaborations, we are making our ambitions a reality.
Our parent company Johnson & Johnson has been ranked number one in the Pharmaceutical category of FORTUNE magazine’s World’s Most Admired list (http://fortune.com/worlds-most-admired-companies/johnson-johnson/) for the last five consecutive years, based on innovation, social responsibility, and quality of products/services.
Find out more about working at Janssen Oncology.
Revolutionise your career in oncology and apply for a job at Janssen here.
 Johnson & Johnson. Johnson & Johnson Named a 2018 Fortune World's Most Admired Company. Available at: https://www.jnj.com/latest-news/johnson-johnson-named-a-2018-fortune-worlds-most-admired-company. Last accessed: September 2018.